Responses
Clinical and epidemiological research
Concise report
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study
Compose a Response to This Article
Other responses
No responses have been published for this article.